Role of Pharmacokinetics in Chronotherapeutics

Lu, Danyi; Wang, Yi; Chen, Menglin; Zhao, Huan; Dong, Dong

doi:10.1007/978-981-15-8807-5_9

Cited by 2 publications

(2 citation statements)

References 303 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is the next enzyme after alcohol dehydrogenase in the major pathway of alcohol metabolism ( Wu et al, 2020 ; NCBI, 2021 ). In addition to alcohol, many drugs can be metabolized by ALDHs, such as EMB, and its L-isomer is metabolized by liver ALDHs to form an aldehyde (oxidative) metabolite.…”

Section: Resultsmentioning

confidence: 99%

“…In addition to alcohol, many drugs can be metabolized by ALDHs, such as EMB, and its L-isomer is metabolized by liver ALDHs to form an aldehyde (oxidative) metabolite. The oxidation of aldehydes is generally considered a detoxification process, and a decrease in the rate of the mechanism could affect the risk of toxicity ( Wu et al, 2020 ). The association between the ALDH1A1 polymorphism and incidence of anti-TB drug-induced liver injury (ATDILI) was investigated ( Chang et al, 2018 ; Zhong et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

et al. 2023

View full text Add to dashboard Cite

The World Health Organization (WHO) stated that ensuring access to effective and optimal treatment is a key component to eradicate tuberculosis (TB) through the End TB Strategy. Personalized medicine that depends on the genetic profile of an individual is one way to optimize treatment. It is necessary because of diverse drug responses related to the variation in human DNA, such as single-nucleotide polymorphisms (SNPs). Ethambutol (EMB) is a drug widely used as the treatment for Mycobacterium Tuberculosis (Mtb) and/non-tuberculous mycobacteria and has become a potential supplementary agent for a treatment regimen of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. In human genetic polymorphism studies of anti-tuberculosis, the majority focus on rifampicin or isoniazid, which discuss polymorphisms related to their toxicity. Whereas there are few studies on EMB, the incidence of EMB toxicity is lower than that of other first-line anti-TB drugs. To facilitate personalized medicine practice, this article summarizes the genetic polymorphisms associated with alterations in the pharmacokinetic profile, resistance incidence, and susceptibility to EMB toxicity. This study includes 131 total human studies from 17 articles, but only eight studies that held in the low-middle income country (LMIC), while the rest is research conducted in developed countries with high incomes. Personalized medicine practices are highly recommended to maintain and obtain the optimal therapeutic effect of EMB.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

et al. 2023

View full text Add to dashboard Cite

show abstract

Pharmacokinetics-based Chronotherapy

Wang

2022

CDM

View full text Add to dashboard Cite

Dosing time-dependency of pharmacokinetics (or chronopharmacokinetics) has been long recognized. Studies in recent years have revealed that diurnal rhythmicity in expression of drug-metabolizing enzymes and transporters (DMETs) are key factors determining chronopharmacokinetics. In this article, we briefly summarize current knowledge with respect to circadian mechanisms of DMETs and discuss how rhythmic DMETs are translated to drug chronoeffects. More importantly, we present our perspectives on pharmacokinetics-based chronotherapy.

show abstract

Role of Pharmacokinetics in Chronotherapeutics

Cited by 2 publications

References 303 publications

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

Pharmacokinetics-based Chronotherapy

Contact Info

Product

Resources

About